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ABSTRACT 
The Synergistic Effects of Methylphenidate on the Behavioral Effects of Nicotine 
by  
Kristen K. Leedy 
One of the most common childhood disorders, attention-deficit hyperactivity disorder (ADHD) 
places individuals at a higher risk for nicotine (NIC) dependence. Approximately 37.2% of 
individuals with ADHD currently smoke compared to the 18.3% of individuals with no record of 
mental illness. Methylphenidate (MPH; Trade name Ritalin) is the most commonly prescribed 
treatment for ADHD. Research regarding the synergistic effects of MPH and NIC, however, is 
divided. Some research indicates that MPH may enhance susceptibility to NIC effects, whereas 
other studies report that MPH may inhibit sensitization to NIC. The present study examines the 
effects of pre-exposure to MPH (1.0 mg/kg) on the behavioral effects of NIC (0.5 mg/kg) in 
adolescent male and female Sprague-Dawley rats. We used behavioral sensitization and 
conditioned place preference (CPP) on animals postnatal day (P)28-50; this is defined as 
adolescence in rats. For behavioral sensitization, results revealed a significant interaction 
between day of testing, drug pre-exposure, and adolescent drug treatment (p = .004). On the 
other hand, CPP results revealed a significant interaction between adolescent drug treatment and 
drug pre-exposure (p = .031). Findings suggest that pre-exposure to MPH reduces behavioral 
sensitization to NIC during adolescence.  In addition, results indicate that MPH enhances NIC 
CPP in adolescent male and female rats, suggesting that MPH may enhance the rewarding effect 
of NIC.  
 Keywords: Methylphenidate, Nicotine, Ritalin, Conditioned Place Preference, 
Adolescence, Sensitization 
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INTRODUCTION 
Compared to those without psychiatric disorders, individuals with ADHD are at a higher 
risk for smoking (Lambert & Hartsough, 1998; Molina & Pelham, 2003; Milberger et al., 1997; 
McClave et al., 2010). About 2.5 - 4% of the adult population is affected by ADHD (Kessler et 
al., 2006; McClave et al., 2010; Simon et al., 2009). In an analysis of findings from the National 
Health Interview Survey, McClave et al. (2010) reported that 37.2% of individuals with ADHD 
currently smoke compared to the 18.3% of individuals with no record of mental illness. Previous 
research indicates that a greater proportion of individuals with ADHD start smoking at a younger 
age and experience greater difficulty quitting in comparison to individuals without ADHD 
(Humfleet et al., 2005; Lee, Humphreys, Flory, & Glass, 2011; McLernon & Kollins, 2008). The 
National Comorbidity Survey Replication study reported that ADHD, in regards to childhood 
externalizing disorders, was one of the strongest predictors of nicotine use/dependence in 
adulthood (Glantz et al., 2009). Although research has failed to determine why individuals with 
ADHD are more likely to smoke, some researchers posit that these individuals may be self-
medicating their symptoms (Gehricke et al., 2007; Khantzian, 1997; Milberger et al., 1997). This 
supposition has been supported by research indicating that the nicotine patch and nicotinic 
agonists do alleviate certain ADHD symptoms (Gehricke et al., 2006, 2009; Levin et al., 1996; 
Wilens et al., 1999, 2006).  
Methylphenidate (MPH) is the most widely prescribed treatment for cases of ADHD in 
children and adults (Findling & Dodgin, 1998; Goldman, Genel, Bezma, & Slanetz, 1998; Zito, 
Sater, dosReis, Gardner, Boles, & Lynch, 2000). However, despite its widespread use, Urban and 
Gao (2013) found that MPH may cause impairments in prefrontal functioning and neural 
plasticity. In addition, Maier et al. (2013) reported that ADHD medications are used by students 
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to enhance cognitive performance, with MPH being the most commonly used. Abusing 
stimulants such as MPH has serious implications; psychostimulants have been found to 
significantly alter neuron functioning and transmission, increasing extracellular levels of 
dopamine (DA), serotonin, and norepinephrine (Angelucci et al., 2009). Calipari and Jones 
(2014) reported that MPH abuse may cause changes in the DA system, eventually leading up to 
the abuse of other addictive substances. 
Even though research indicates that children and adults respond differently to MPH 
(Torres-Reveron & Dow-Edwards, 2005), in recent years there has been a significant increase in 
MPH prescriptions for ADHD (Olfson, Gameroff, Marcus, & Jensen, 2003; Safer, Zito, & Fine, 
1996; Zito et al., 2000). Acting as a stimulant, MPH increases pre-synaptic dopamine release 
while simultaneously blocking dopamine reuptake (Volkow, Fowler, Wang, Ding, & Gatley, 
2002). Some research suggests that ADHD may result from problems with dopamine transporter 
(DAT) availability (Cheon et al., 2003; Dougherty et al., 1999; Krause, 2008; Krause et al., 
2000). MPH blocks DAT, which is believed to be how MPH essentially treats ADHD symptoms 
(Krause et al., 2000). Our lab has shown that MPH upregulates the DAT (Cummins et al., 2013). 
Reports have shown that MPH should cause a reduction in smoking behaviors if the 
medication (as opposed to nicotine) reduces ADHD symptomology (Winhusen et al., 2010). In 
support of these findings, some research has suggested that stimulants, such as MPH, may act as 
an aid to smoking cessation. Monuteaux et al. (2007) found promising results while examining 
the efficacy of buproprion as an adult smoking cessation aid in ADHD children. Although 
bupropion is already a smoking cessation aid, results did suggest that other stimulants may be 
effective as well. Additional support for this was found by Hammerness et al. (2013) in an open-
label, long-term clinical trial of extended-release MPH in adolescents diagnosed with ADHD. 
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Results indicated that 10 months of treatment, on average, was correlated with a low rate of 
cigarette smoking. In fact, this rate was similar to individuals without ADHD as well as 
individuals under treatment for their ADHD (Hammerness et al., 2013).  
However, some research has suggested that MPH increases smoking behaviors even in 
individuals without ADHD. Rush et al. (2005) and Vansickel et al. (2007, 2009) demonstrated 
that non-ADHD individuals saw an increase in smoking when treated with MPH. In these 
studies, individuals treated with at least one dose of MPH saw an increase in cigarette puffs in 
comparison to the placebo group (Rush et al., 2005; Vansickel et al., 2007, 2009). Other studies 
have demonstrated that MPH can elicit a change in preference for cigarettes over money (Stoops 
et al., 2011). Therefore, there appears to be some disagreement in the literature as to whether 
MPH actually blunts the rewarding effects of nicotine or changes the brain’s reward system, 
making it vulnerable. 
The present study examined the effect of pre-exposure to MPH on the behavioral effects 
of NIC. We focused our research on the vulnerable developmental period of adolescence; in rats 
this is defined in postnatal days (P) ranging from P28 to 50 (Spear, 2000; Laviola et al., 2003). 
We used two behavioral tests: behavioral sensitization and conditioned place preference (CPP). 
Behavioral sensitization is a behavioral test of the augmented motor response that occurs with 
repeated intermittent exposure to a drug. CPP is a behavioral test of the associative effects of 
drugs. The present experiment also utilized a clinically relevant dose of MPH (1.0 mg/kg; 
Devilbiss & Berridge, 2008) that results in brain plasma levels relevant to the MPH-medicated 
ADHD population. In addition, we employed a dose of nicotine (NIC; 0.5 mg/kg) that has been 
shown to produce both behavioral sensitization and CPP (Kelley & Rowan, 2004; Justo et al., 
2010; Fanous, Lacagnina, Nikulina, & Hammer, 2011). Regarding sensitization, a significant 
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increase in dopamine release and activation of the mesolimbic dopamine projections occurs after 
chronic psychostimulant exposure (Boileau et al., 2006); the locomotor activity that results can 
be measured from horizontal and vertical movements, which indicate psychomotor sensitization 
(Tirelli, Laviola, & Adriani, 2003; Fanous et al., 2011). Unlike behavioral sensitization, CPP is a 
behavioral paradigm that allows researchers to test the rewarding effects of drugs in rodents. 
METHODS 
Subjects. Male and female adolescent Sprague-Dawley rats were used as subjects and 
raised in the Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) accredited animal colony at East Tennessee State University. All animals were 
given food and water ad libitum and housed in a climate controlled vivarium on a 12 hour on/off 
light dark cycle. All behavioral testing was conducted during the light cycle. All procedures were 
approved by the ETSU Committee on Animal Care which is consistent with the NIH Guide on 
Care and Use of Animals. 
Drug pre-exposure. On P28, drug pre-exposure began and continued throughout the 
remainder of the experiment. Animals were ip administered daily with either MPH (1.0 mg/kg) 
or SAL in the morning at approximately 8 am; animals were randomly assigned to each group. 
This dosing regimen was chosen because it mimics the average MPH prescription; there are five 
days “on,” two days “off,” designed to be consistent with school day dosing in humans. 
Behavioral testing began on P42 in two different sets of animals; one group was tested on 
behavioral sensitization and the other was assessed using the CPP paradigm. 
Behavioral Sensitization. On P42, behavioral sensitization began with habituation. For 
three consecutive days, each animal was ip injected with SAL and placed into the locomotor 
arena after a 10 minute delay. The purpose of the delay was to allow for proper drug distribution 
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before testing. Activity counts were then recorded for 10 minutes using Any Maze behavioral 
scanning software (Stoelting Co., Wood Dale, IL). This software superimposes a virtual grid 
onto the locomotor arena, while keeping track of the number of “grid-breaks” the animal makes. 
Here our dependent measure was activity counts; essentially, the number of grid-breaks is 
analogous to level of activity. On P45, NIC (or SAL) treatment began. Animals were ip injected 
with either SAL or NIC (0.5 mg/kg). After a 10 minute delay, each animal’s activities were once 
again recorded for 10 minutes. All animals were behaviorally tested in a (72 cm/side) square 
locomotor arena and allowed to move around freely.    
  Conditioned Place Preference (CPP). For behavioral testing on the CPP paradigm, a 
different set of animals was used to examine the effects of pre-exposure to MPH on the reward-
aspect of the drug. The CPP apparatus used was a three-chambered wooden box; the center 
compartment was painted solid gray, while the outer two compartments are distinct from one 
another. Each compartment was the same size (90 cm/side), but unique in tactile surface and 
visual appearance. In addition, the gray compartment had wooden flooring; the remaining two 
contexts had either wire mesh or metal dowel rod flooring with either black/white horizontal or 
vertical stripes on the walls. These three contexts were separated by removable dividers. The 
difference in environmental contexts allows the animal the ability to distinguish between 
contexts and associate one with the rewarding effect of a drug such as NIC. Again Any Maze 
behavioral scanning software was used to track animal movements, but here the main focus was 
how much time the animal spent in the context paired with NIC as compared to SAL controls on 
the post-conditioning test. The dependent measure was calculated by subtracting the percent of 
time spent in the paired context during pre-test from the percent of time spent in the paired 
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context during the post-test. Time spent in the middle compartment was not considered time 
spent outside the paired context. 
 Two initial preference tests were conducted P42-43 with the dividers removed. The 
average time spent in each compartment was recorded, revealing any natural preferences, and 
animals were conditioned against their natural preference. After determining initial preferences 
by averaging performance on these two initial preference tests, conditioning began on P44 and 
occurred every day; each animal received a session in the morning and one later in the afternoon. 
Animals were given either NIC or SAL ip and were placed into the locomotor arena after a 10-
minute delay for a 10 minute test. For conditioning, dividers were inserted into the apparatus and 
each animal was assigned to their unpaired context in the morning session and administered 
SAL. During the afternoon sessions, animals were assigned to their paired context and 
administered NIC or SAL depending on group assignment. Conditioning occurred every 
consecutive day for eight days from P44-50. On P51, a post-conditioning preference test was 
conducted; this test was identical in procedure to the initial pre-conditioning preference tests. 
Dividers are once again removed and animals receive SAL ip 10 minutes before being tested for 
10 minutes.   
RESULTS 
 In regards to behavioral sensitization, we were unable to find any sex differences, so we 
collapsed across the factor of sex. A three-way ANOVA revealed a significant three-way 
interaction between drug pre-exposure x adolescent drug treatment x day of testing (p = .004). At 
day one of testing, no significant differences were found among treatment groups; therefore, 
acute NIC treatment did not change locomotor activity regardless of MPH pre-exposure (see 
Figure 1). However, at day 9 SAL-NIC animals displayed the highest activity counts in 
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comparison to all other groups besides MPH-SAL. These animals demonstrated behavioral 
sensitization to NIC. Compared to SAL-NIC animals, NIC animals pre-exposed to MPH actually 
showed a decrease in locomotor activity at day 9. These results suggest that pre-exposure to 
MPH reduces behavioral sensitization to NIC in male and female adolescent rats compared to 
controls. In other words, MPH appears to reduce the behavioral activating effects of NIC. 
 
Figure 1. Activity counts are represented as a function of day of testing and drug condition (** 
indicates group is greater than MPH-NIC and SAL-SAL, p < .05; * indicates group is greater 
than SAL-SAL, p < .05). 
 For analysis of CPP, we again collapsed across the factor of sex after discovering no sex 
differences. A two-way ANOVA revealed a significant interaction between drug pre-exposure 
and adolescent drug treatment (p = .031). In comparison to other groups, animals pre-exposed to 
MPH and treated with NIC displayed the greatest preference for the context paired with NIC (see 
Figure 2). In addition, SAL pre-exposed animals displayed nicotine CPP in that this group 
displayed a significant preference as compared to SAL-treated controls. The results suggest that 
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pre-exposure to MPH may enhance NIC CPP in adolescent male and female rats compared to 
controls. Essentially, MPH appears to enhance the reward aspect of NIC. 
 
Figure 2. The percent time difference spent in the paired context on the pre and post-
conditioning preference tests is presented as a function of condition (** indicates MPH-NIC 
group is significantly greater than all other groups, p < .05; * indicates SAL-NIC is greater than 
SAL-SAL and MPH-SAL, p < .05). 
DISCUSSION 
 At a clinically relevant dose, MPH appears to reduce behavioral sensitization to NIC in 
adolescent male and female rats. Thus, we failed to support our original hypothesis that pre-
exposure to MPH would enhance the behavioral effects of NIC. On the other hand, we also 
demonstrated that pre-exposure to MPH enhances NIC CPP in male and female adolescent rats. 
This supports our original hypothesis that MPH would enhance NIC CPP in adolescent male and 
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female rats. This finding suggests that MPH enhances the reward aspect of NIC. Unfortunately, 
due to a fairly low number of males, we were required to further generalize our findings and 
exclude sex differences from our final analyses. Preliminary data from our lab has suggested that 
females are affected more robustly by this synergistic relationship. Also of interest, we 
demonstrated NIC CPP in a non-biased CPP procedure, the first instance of NIC CPP outside a 
biased paradigm.   
 Future research should continue to tease apart these complex findings; although the 
research is divided, it is not necessarily inconsistent. The high count of locomotor activity in 
animals pre-exposed to MPH is likely a result of an increase in stereotypic behaviors. 
Stereotypies are inappropriate, repetitive behaviors that serve no real biological purpose or 
function (Garner, 2005; Turner, 1997); an increase in stereotypic behavior and hyperlocomotion 
is indicative of increased dopamine activity (Creese and Iversen, 1974; Kelley et al., 1975; 
Kelley & Iversen, 1976; Lucot et al., 1980). Wallace, Gudelsky, and Vorhees (1999) 
demonstrated that repeated high-dose administration of methamphetamine increased stereotypic 
behaviors and increased the release of DA. The animals in sensitization are likely displaying 
MPH-induced stereotypy as a response to increased DA activity in the brain.  
 Finally, MPH has been shown to affect neurotrophic factors, such as brain-derived 
neurotrophic factor (BDNF; Brown et al., 2012). BDNF is found throughout the brain and plays 
a direct role in neuronal growth, function, and development (Reichardt, 2006). MPH may 
increase levels of BDNF in the brain, affecting brain areas that mediate drug reinforcement. This 
in turn, could result in an increased DA response. 
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